Is MESO a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Ryoncil's first full year of sales, with ryoncil net revenue (fy2026, year to june 30, 2026) at ~$115M, preliminary and unaudited. The bear case rests on nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Ryoncil's first full year of sales. Ryoncil generated roughly $115 million of net revenue in the fiscal year ended June 30, 2026, its first complete year on the market, with about $66.5 million of that in the second half.

Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. The adult GvHD, chronic low back pain, LVAD-related bleeding and Duchenne muscular dystrophy programs are all unapproved, and Mesoblast has a long history of FDA setbacks, including the 2020 complete response letter that preceded a four-year delay to approval. Ordinary shares roughly doubled from about 650 million in mid-2022 to about 1.28 billion in mid-2025, and the company has said it will need additional capital beyond the next twelve months, so further dilution is a reasonable expectation. Book equity of about $575 million at December 31, 2025 is almost entirely intangible assets and goodwill at roughly $569 million, which means the price-to-book ratio understates how little tangible net asset backing there is. Prior management guidance and pipeline timelines have slipped repeatedly, and the fiscal 2026 revenue figures are preliminary and subject to completion of the audit.

Melbourne-based cell-therapy company selling Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory graft-versus-host disease in children.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Ryoncil's first full year of sales) stalling in the reported numbers rather than in the narrative, the risk above (nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Mesoblast develops allogeneic, or off the shelf, mesenchymal stromal cell medicines that dampen severe inflammation. Ryoncil (remestemcel-L-rknd) is its one approved product, cleared by the FDA in December 2024 for steroid-refractory acute graft versus host disease in children two months and older. It was the first mesenchymal stromal cell therapy ever approved in the United States, and it is given as eight intravenous infusions over four weeks.

Yes. MESO is a sponsored American depositary share listed on the Nasdaq Global Select Market, and each ADS currently represents ten Mesoblast ordinary shares. The ratio was five ordinary shares per ADS until it was changed to ten during the 2024 fiscal year, so per-ADS price history from before that change is not directly comparable. Average volume runs around 170,000 to 190,000 ADS a day, so this is a normally traded Nasdaq listing rather than a thin over-the-counter quote.

They are claims on the same company. MSB is the Australian Securities Exchange line in ordinary shares and Australian dollars, and it is the primary listing. MESO is the Nasdaq ADS line in U.S. dollars, with each ADS backed by ten ordinary shares held by a depositary bank. Most U.S. brokers, including those Walnut connects to, will only offer the MESO line, and the depositary charges periodic fees against ADS holders.